"Since the early days when Andreas GrÃ¼ntzigs delivered his first balloon, not much has changed in the technique we use to perform coronary percutaneous procedures," said Dr. Weisz. "For the first time in my career, I am able to perform interventions without the strain of a heavy lead apron. Using the CorPath 200 System, I am able to perform percutaneous coronary interventions (PCI) procedures precisely and effectively, while sitting comfortably in a radiation protected interventional cockpit. The technology has the potential to change the standard of care and revolutionize the way we perform PCI procedures."
Corindus Vascular Robotics will also host hands-on demonstrations of the CorPath 200 System at booth 505. To reserve your booth presentation of the CorPath 200 System, please call 508.653.3335 x200 or email email@example.com.
As noted in a recent article published in in the Journal of Cardiovascular Translational Research, "Robotic-Assisted Percutaneous Coronary Intervention-Filling an Unmet Need" by Joseph P. Carrozza, M.D., Professor of Medicine at Tufts University School of Medicine, Vice President of Cardiovascular Medicine at Steward Healthcare Systems, Chief of Cardiovascular Medicine at St. Elizabeths Medical Center, the cumulative exposure to ionizing radiation, orthopedic injuries resulting from lead aprons, and fatigue from standing for hours during the procedure, makes the catheterization laboratory a "high-risk workplace" for the interventional cardiologist. In fact, data published in the Catheterization and Cardiovascular Intervention journal, an interventional cardiologists daily exposure to radiation and the physical stresses inherent in the cath lab can lead to occupational health risks including orthopedic problems, cataracts and cancer.
The CorPath 200 System allows for controlled robotic-assisted placement of coronary guidewires and stent/balloon catheters from an ergonomically optimized interventional cockpit. The lead-lined cockpit protects the operator from radiation exposure. The comfortable seated position in front of the cockpit monitors provides enhanced visualization of the angiography screen while reducing fatigue and minimizes head, neck and back strain.
"The interest in the interventional cardiology community continues to reinforce the value of the robotic-assisted PCI," said David M. Handler, President and CEO of Corindus. "We are excited with the positive experience the physicians have had so far using the CorPath 200 System during the PRECISE trial."
Corindus is the global technology leader in robotic-assisted percutaneous coronary interventions. The Companys CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation shielded interventional cockpit. The CorPath open-platform technology and intellectual property will enable Corindus to address other segments of the vascular market, including peripheral, neuro and structural heart applications. Additional information can be found at: http://www.corindus.com
NOTE: The CorPath 200 System is an investigational device and limited by federal law to investigational use only.